New hope for advanced melanoma: T3011 trial launches

NCT ID NCT06214156

Recruiting now Disease control Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 2 times

Summary

This study tests a new drug, T3011, in 42 people with advanced melanoma that has spread. The main goals are to check safety and see if tumors shrink. Participants must have measurable tumors and be in good overall health.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma metastatic melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED MELANOMA

Contacts and locations

Locations

Beijing Cancer Hospital
RECRUITING

Beijing, China
Chengdu Shangjin Nanfu Hospital
RECRUITING

Chengdu, China
Fujian Cancer Hospital
RECRUITING

Fuzhou, China
Jilin Cancer Hospital
RECRUITING

Changchun, China
Sun Yat-sen University Cancer Center
RECRUITING

Zhongshan, China
The First Affiliated Hospital of Bengbu Medical College
RECRUITING

Bengbu, China
The Third People's Hospital of Zhengzhou
RECRUITING

Zhengzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.